Pyronaridine–artesunate | Artemether–lumefantrine | P value* | |
---|---|---|---|
Pfs25 QT-NASBA prevalence, % (no./No.) | |||
Day 0 | 95.3 (81/85) | 94.7 (71/75) | 1.000 |
Day 3 | 37.0 (30/81) | 31.0 (22/71) | 0.433 |
Day 7 | 21.7 (18/83) | 16.7 (12/72) | 0.430 |
Day 14 | 15.2 (12/79) | 7.58 (5/66) | 0.156 |
Pfs25 QT-NASBA density, median (IQR)a | |||
Day 0 | 3.23 (0.68–18.1) | 6.36 (1.19–22.2) | 0.229 |
Day 3 | 3.86 (0.33–16.4) | 3.73 (0.33–6.91) | 0.630 |
Day 7 | 2.82 (1.17–33.5) | 0.74 (0.23–12.9) | 0.150 |
Day 14 | 6.19 (2.10–27.2) | 1.45 (0.65–1.69) | 0.092 |
Pfs25 qRT-PCR prevalence, % (no./No.) | |||
Day 0 | 97.7 (83/85) | 100 (75/75) | 0.499 |
Day 3 | 30.9 (25/81) | 33.8 (24/71) | 0.699 |
Day 7 | 19.3 (16/83) | 16.7 (12/72) | 0.674 |
Day 14 | 13.9 (11/79) | 6.06 (4/66) | 0.122 |
Pfs25 qRT-PCR density, median (IQR)a | |||
Day 0 | 2.88 (0.85–5.24) | 1.94 (0.77–5.35) | 0.568 |
Day 3 | 0.58 (0.30–1.66) | 0.30 (0.14–0.62) | 0.039 |
Day 7 | 0.78 (0.33–15.5) | 0.28 (0.16–0.83) | 0.126 |
Day 14 | 0.33 (0.14–6.42) | 0.12 (0.08–0.90) | 0.322 |
PfMGET qRT-PCR prevalence (%) (no./No.) | |||
Day 0 | 35.3 (30/85) | 41.3 (31/75) | 0.433 |
Day 3 | 34.6 (28/81) | 36.6 (26/71) | 0.792 |
Day 7 | 31.3 (26/83) | 30.6 (22/72) | 0.918 |
Day 14 | 22.8 (18/79) | 19.7 (13/66) | 0.652 |
PfMGET qRT-PCR density, median (IQR)b | |||
Day 0 | 0.94 (0.11–14.1) | 0.48 (0.21–10.1) | 0.920 |
Day 3 | 2.55 (0.21–11.0) | 0.82 (0.17–5.07) | 0.341 |
Day 7 | 3.23 (0.21–8.95) | 1.22 (0.19–11.5) | 0.551 |
Day 14 | 1.81 (0.30–11.2) | 1.51 (0.66–6.91) | 0.779 |
Total qRT-PCR prevalence, % (no./No.) | |||
Day 0 | 97.7 (83/85) | 100 (75/75) | 0.499 |
Day 3 | 42.0 (34/81) | 43.7 (31/71) | 0.841 |
Day 7 | 32.5 (27/83) | 31.9 (23/72) | 0.920 |
Day 14 | 25.3 (20/79) | 21.2 (14/66) | 0.560 |
Total qRT-PCR density, median (IQR)c | |||
Day 0 | 3.23 (0.86–7.54) | 2.24 (0.91–6.13) | 0.642 |
Day 3 | 1.20 (0.24–11.0) | 1.06 (0.11–5.21) | 0.248 |
Day 7 | 3.47 (0.26–15.5) | 1.69 (0.27–12.3) | 0.631 |
Day 14 | 1.66 (0.30–14.6) | 1.34 (0.55–7.00) | 0.662 |